Punt CJ - Search Results

1

Prophylactic G-CSF and antibiotics enable a significant dose-escalation of triplet-chemotherapy in non-small cell lung cancer.

Timmer-Bonte JN, Punt CJ, vd Heijden HF, van Die CE, Bussink J, Beijnen JH, Huitema AD, Tjan-Heijnen VC. Timmer-Bonte JN, et al. Among authors: punt cj. Lung Cancer. 2008 May;60(2):222-30. doi: 10.1016/j.lungcan.2007.10.001. Epub 2007 Nov 19. Lung Cancer. 2008. PMID: 18006110 Clinical Trial.

2

Continuous infusion of high-dose 5-fluorouracil in combination with leucovorin and recombinant interferon-alpha-2b in patients with advanced colorectal cancer. A Multicenter Phase II study.

Punt CJ, Burghouts JT, Croles JJ, van Liessum PA, de Mulder PH, Kamm Y. Punt CJ, et al. Cancer. 1993 Oct 1;72(7):2107-11. doi: 10.1002/1097-0142(19931001)72:7<2107::aid-cncr2820720708>3.0.co;2-m. Cancer. 1993. PMID: 8374869 Clinical Trial.

3

Phase IB study of doxorubicin in combination with the multidrug resistance reversing agent S9788 in advanced colorectal and renal cell cancer.

Punt CJ, Voest EE, Tueni E, Van Oosterom AT, Backx A, De Mulder PH, Hecquet B, Lucas C, Gerard B, Bleiberg H. Punt CJ, et al. Br J Cancer. 1997;76(10):1376-81. doi: 10.1038/bjc.1997.563. Br J Cancer. 1997. PMID: 9374386 Free PMC article. Clinical Trial.

4

A clinical pharmacokinetics study of carzelesin given by short-term intravenous infusion in a phase I study.

van Tellingen O, Punt CJ, Awada A, Wagener DJ, Piccart MJ, Groot Y, Schaaf LJ, Henrar RE, Nooijen WJ, Beijnen JH. van Tellingen O, et al. Among authors: punt cj. Cancer Chemother Pharmacol. 1998;41(5):377-84. doi: 10.1007/s002800050754. Cancer Chemother Pharmacol. 1998. PMID: 9523733 Clinical Trial.

5

Phase I and pharmacokinetic study of E7070, a novel sulfonamide, given at a daily times five schedule in patients with solid tumors. A study by the EORTC-early clinical studies group (ECSG).

Punt CJ, Fumoleau P, van de Walle B, Faber MN, Ravic M, Campone M. Punt CJ, et al. Ann Oncol. 2001 Sep;12(9):1289-93. doi: 10.1023/a:1012287111922. Ann Oncol. 2001. PMID: 11697842 Free article. Clinical Trial.

6

A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors.

Giaccone G, Punt CJ, Ando Y, Ruijter R, Nishi N, Peters M, von Blomberg BM, Scheper RJ, van der Vliet HJ, van den Eertwegh AJ, Roelvink M, Beijnen J, Zwierzina H, Pinedo HM. Giaccone G, et al. Among authors: punt cj. Clin Cancer Res. 2002 Dec;8(12):3702-9. Clin Cancer Res. 2002. PMID: 12473579 Clinical Trial.

7

Phase I and pharmacokinetic study of CCI-779, a novel cytostatic cell-cycle inhibitor, in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors.

Punt CJ, Boni J, Bruntsch U, Peters M, Thielert C. Punt CJ, et al. Ann Oncol. 2003 Jun;14(6):931-7. doi: 10.1093/annonc/mdg248. Ann Oncol. 2003. PMID: 12796032 Free article. Clinical Trial.

8

RFS2000 (9-nitrocamptothecin) in advanced small cell lung cancer, a phase II study of the EORTC New Drug Development Group.

Punt CJ, de Jonge MJ, Monfardini S, Daugaard G, Fiedler W, Baron B, Lacombe D, Fumoleau P; EORTC New Drug Development Group. Punt CJ, et al. Eur J Cancer. 2004 Jun;40(9):1332-4. doi: 10.1016/j.ejca.2004.02.016. Eur J Cancer. 2004. PMID: 15177492 Clinical Trial.

9

Effects of nicotinamide and carbogen in different murine colon carcinomas: immunohistochemical analysis of vascular architecture and microenvironmental parameters.

van Laarhoven HW, Bussink J, Lok J, Punt CJ, Heerschap A, van Der Kogel AJ. van Laarhoven HW, et al. Among authors: punt cj. Int J Radiat Oncol Biol Phys. 2004 Sep 1;60(1):310-21. doi: 10.1016/j.ijrobp.2004.05.014. Int J Radiat Oncol Biol Phys. 2004. PMID: 15337570

10

Semi-physiological model describing the hematological toxicity of the anti-cancer agent indisulam.

van Kesteren C, Zandvliet AS, Karlsson MO, Mathôt RA, Punt CJ, Armand JP, Raymond E, Huitema AD, Dittrich C, Dumez H, Roché HH, Droz JP, Ravic M, Yule SM, Wanders J, Beijnen JH, Fumoleau P, Schellens JH. van Kesteren C, et al. Among authors: punt cj. Invest New Drugs. 2005 Jun;23(3):225-34. doi: 10.1007/s10637-005-6730-3. Invest New Drugs. 2005. PMID: 15868378

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

496 results

Search Page

Filters